Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

MLA

Wehling, C., et al. “Monitoring of Complement Activation Biomarkers and Eculizumab in Complement-Mediated Renal Disorders.” Clinical & Experimental Immunology, vol. 187, no. 2, Feb. 2017, pp. 304–15. EBSCOhost, https://doi.org/10.1111/cei.12890.

APA

Wehling, C., Amon, O., Bommer, M., Hoppe, B., Kentouche, K., Schalk, G., Weimer, R., Wiesener, M., Hohenstein, B., Tönshoff, B., Büscher, R., Fehrenbach, H., Gök, Ö. ‐N., & Kirschfink, M. (2017). Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clinical & Experimental Immunology, 187(2), 304–315. https://doi.org/10.1111/cei.12890

Chicago

Wehling, C., O. Amon, M. Bommer, B. Hoppe, K. Kentouche, G. Schalk, R. Weimer, et al. 2017. “Monitoring of Complement Activation Biomarkers and Eculizumab in Complement-Mediated Renal Disorders.” Clinical & Experimental Immunology 187 (2): 304–15. doi:10.1111/cei.12890.